[go: up one dir, main page]

NO995257L - Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome - Google Patents

Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome

Info

Publication number
NO995257L
NO995257L NO995257A NO995257A NO995257L NO 995257 L NO995257 L NO 995257L NO 995257 A NO995257 A NO 995257A NO 995257 A NO995257 A NO 995257A NO 995257 L NO995257 L NO 995257L
Authority
NO
Norway
Prior art keywords
inhibitor
precursor
phenylalanine
dopamine
enkephalinase
Prior art date
Application number
NO995257A
Other languages
Norwegian (no)
Other versions
NO995257D0 (en
Inventor
Kenneth Blum
David E Comings
John L Ivy
Original Assignee
Kenneth Blum Inc
Univ Texas
Hope Nat Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Blum Inc, Univ Texas, Hope Nat Medical Center filed Critical Kenneth Blum Inc
Publication of NO995257D0 publication Critical patent/NO995257D0/en
Publication of NO995257L publication Critical patent/NO995257L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Det beskrives forbedring av konsentrasjonsprosessering ved administrering av endorfinaseinhibitor eller enke- falinaseinhibitor, og valgfritt en dopaminforløper, eller en serotoninforløper, en GABA-forløper, eller en endorfin- eller enkefalinase-frigjører, eller visse urteforbindelser inkluderende Rhodediola rosea ekstrakt (Pharmaline) og/ eller Huperzine. Disse forbindelser fremmer gjenvinning av normal neurotransmitterfunksjon, og hvor materialene kombinert fremmer frigivelse av dopamin ved nucleus accumbens og er ikke vanedannende. Anvendelse av dopamin- forløpere L-phenylalanin, eller L-tyrosin, enkefalinase- inhibitoren D-fenylalanin, og/eller serotonin-forløper hydroksytryptofan og en naturlig acetylcholenesterase- inhibitor og kromsalter (dvs. picolinat, nicotinat, etc.) er spesielt foretrukket, men ikke begrenset, til å assistere i å frigi symptomer assosiert med fenylalanin- mangel i hjerne.Enhancement of concentration processing is described by administration of endorphinase inhibitor or enkephalinase inhibitor, and optionally a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase release, or certain herbal compounds, including Rhodediola or Huperzine. These compounds promote the recovery of normal neurotransmitter function, and where the materials combined promote release of dopamine by nucleus accumbens and are not addictive. Use of dopamine precursors L-phenylalanine, or L-tyrosine, the enkephalinase inhibitor D-phenylalanine, and / or serotonin precursor hydroxytryptophan and a natural acetylcholesterol esterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is particularly preferred. but not limited, to assist in releasing symptoms associated with phenylalanine deficiency in the brain.

NO995257A 1997-04-29 1999-10-28 Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome NO995257L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4439497P 1997-04-29 1997-04-29
PCT/US1998/008684 WO1998048785A2 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment

Publications (2)

Publication Number Publication Date
NO995257D0 NO995257D0 (en) 1999-10-28
NO995257L true NO995257L (en) 1999-12-27

Family

ID=21932148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995257A NO995257L (en) 1997-04-29 1999-10-28 Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome

Country Status (10)

Country Link
EP (1) EP0979092A2 (en)
JP (1) JP2002511850A (en)
KR (1) KR20010020422A (en)
CN (1) CN1261801A (en)
AU (1) AU7267798A (en)
CA (1) CA2288990A1 (en)
IL (1) IL132634A0 (en)
IS (1) IS5233A (en)
NO (1) NO995257L (en)
WO (1) WO1998048785A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
DE60028841T2 (en) * 2000-12-01 2006-12-28 Be Able, Llc behavior chemotherapy
ITRM20010218A1 (en) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION OR TREATMENT OF LEARNING DISORDERS IN CHILDREN AFFECTED BY ATTENTION DEFICIT AND HYPERACTIVE
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
EP2520669A3 (en) * 2005-02-07 2013-02-27 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
KR101029394B1 (en) 2006-09-28 2011-04-15 미쓰비시덴키 가부시키가이샤 Fault detection device, fault detection method and fault detection program
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
WO2009155585A1 (en) * 2008-06-21 2009-12-23 Blumy Kenneth N utragenomics
WO2010005303A2 (en) * 2008-07-07 2010-01-14 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum New indicators of human longevity and biological ageing rate
SG184395A1 (en) 2010-04-01 2012-11-29 Ecole Polytech Device for interacting with neurological tissue and methods of making and using the same
EP2585824A4 (en) * 2010-04-22 2014-01-01 Kenber Llc Genetic risk analysis in reward deficiency syndrome
JP6325254B2 (en) * 2011-09-30 2018-05-16 公益財団法人東京都医学総合研究所 Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
JP2015067581A (en) * 2013-09-30 2015-04-13 国立大学法人京都大学 Probe for multiple resonance
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN103990106A (en) * 2014-06-11 2014-08-20 河北医科大学 Application of cholecystokinin octapeptide in medicine preparation
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
CN104846015B (en) * 2015-05-27 2018-03-27 深圳先进技术研究院 The composition of GABA serotonergic neurons in special heat nucleus accumbens septi and its application in schizophrenia difference behavior is improved
WO2017134587A1 (en) * 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
DE102018114364A1 (en) 2018-06-15 2019-12-19 Susanne Koch Methods and devices for providing a parameter which indicates an increased probability of the occurrence of postoperative delirium
CN109316196B (en) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） Amphetamine stimulant craving assessment method based on virtual reality and electroencephalogram monitoring
CN110507294B (en) * 2019-08-07 2022-02-08 北京安龙脉德医学科技有限公司 First-aid system based on internet information transmission
CN110991044B (en) * 2019-12-03 2023-02-24 北京机电工程研究所 Agent modeling-based aircraft system task reliability assessment method
CN112862751B (en) * 2020-12-30 2022-05-31 电子科技大学 Automatic diagnosis device for autism
CN113332299A (en) * 2021-05-27 2021-09-03 广东湛江海洋医药研究院 Application of salidroside in relieving glucocorticoid-induced osteoporosis
KR102434668B1 (en) * 2022-03-02 2022-08-22 주식회사 국개대표 Feed for pets that can improve separation anxiety symptoms and manufacturing thereof
CN115830001B (en) * 2022-12-22 2023-09-08 抖音视界有限公司 Intestinal tract image processing method and device, storage medium and electronic equipment
CN116310717B (en) * 2023-02-14 2025-06-20 长沙理工大学 Target student network model training method and low-resolution image recognition method
CN116820166B (en) * 2023-06-08 2024-07-19 武汉汉联智控科技有限公司 High-low temperature control flow control system and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity

Also Published As

Publication number Publication date
WO1998048785A9 (en) 1999-05-20
CA2288990A1 (en) 1998-11-05
CN1261801A (en) 2000-08-02
AU7267798A (en) 1998-11-24
WO1998048785A3 (en) 1999-04-01
JP2002511850A (en) 2002-04-16
WO1998048785A2 (en) 1998-11-05
KR20010020422A (en) 2001-03-15
IS5233A (en) 1999-10-28
IL132634A0 (en) 2001-03-19
EP0979092A2 (en) 2000-02-16
NO995257D0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO995257L (en) Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome
Walker et al. The γ‐aminobutyric acid‐B receptor agonist baclofen attenuates responding for ethanol in ethanol‐dependent rats
Murray et al. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function
Tolman Hepatotoxicity of non-narcotic analgesics
Bidaut-Russell et al. Adverse gastrointestinal effects of NSAIDs: consequences and costs
DK0668851T3 (en) Hitherto unknown aryl propionic acid derivative, process for its preparation and use as analgesic
NO964486D0 (en) Use of certain methane bisphosphonic acid derivatives to prevent dissolution of prosthesis and prosthesis migration
Hersi et al. Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study
EP2327451A3 (en) Method for detecting and inhibiting angiogenesis
Li et al. Gallstone recurrence after minimally-invasive cholecystolithotomy with gallbladder reservation: a follow-up of 720 cases
NO980221L (en) Procedure for the treatment of colon adenomas
NO20015932D0 (en) Procedures for treating diabetes
DE60016866D1 (en) METHOD AND DEVICE FOR TREATING DATA DISTURBANCE AND SHARED PLATES IN THE CONTEXT OF DATA SECURITY, SUPPORT AND RECOVERY
Villetti et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways
Krstić et al. Inhibition of Na+/K+-ATPase and Mg2+-ATPase by metal ions and prevention and recovery of inhibited activities by chelators
Jiang et al. Endothelium‐dependent vasorelaxation independent of nitric oxide and K+ release in isolated renal arteries of rats
Yavin et al. Temperature‐mediated interaction of tetanus toxin with cerebral neuron cultures: characterization of a neuraminidase‐insensitive toxin‐receptor complex
Damment Pharmacology of the phosphate binder, lanthanum carbonate
Saag et al. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics
Tiitinen et al. Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid
Teixeira et al. Pharmacological characterization of kinin‐induced relaxation of human corpus cavernosum
Korpela et al. Oral naproxen but not oral paracetamol reduces the need for rescue analgesic after adenoidectomy in children
WO2007022059A3 (en) Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof
Petek et al. Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice
Corrigan Jr et al. Treatment of chronic haemophilic synovitis in humans with D‐penicillamine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application